SCHEMBL2916474

SCHEMBL2916474

CCOC(=O)C1CCCN(C(=O)c2cc(-c3ccc(F)cc3)n(-c3ccc(OC)nc3)n2)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
HPGD P15428 5/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TP53 P04637 2/20 0.49
ESR1 P03372 1/20 0.49
KMT2A Q03164 1/20 0.49
ESR2 Q92731 1/20 0.49
ALDH1A1 P00352 4/20 0.48
PTGS1 P23219 1/20 0.48
EPHX2 P34913 1/20 0.48
PTGS2 P35354 1/20 0.48
LMNA P02545 1/20 0.48
NPSR1 Q6W5P4 1/20 0.48
KDM1A O60341 6/20 0.47
HSD17B10 Q99714 3/20 0.47
MAPT P10636 2/20 0.46
MAPK1 P28482 1/20 0.46
CASP1 P29466 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2917927 0.91 PTGS2 (0.59) NPC1RAB9AKMT2APTGS1EPHX2
SCHEMBL2913285 0.90 KDM1A (0.50) KDM1A
SCHEMBL13637346 0.84 KDM1A (0.51) KDM1A
SCHEMBL2914363 0.84 CHRNA7 (0.44) NPC1RAB9AKMT2AALDH1A1PTGS1
SCHEMBL2921273 0.81 MGLL (0.51) KMT2APTGS1EPHX2PTGS2KDM1A
SCHEMBL13637534 0.81 KDM1A (0.51) KMT2APTGS2KDM1AMAPT
SCHEMBL2915459 0.80 PTGS2 (0.48) KMT2APTGS2KDM1AMAPT
SCHEMBL2913443 0.80 CHRNA7 (0.64) KMT2APTGS1PTGS2
Hydrochloric Acid SCHEMBL2912049 0.80 PTGS2 (0.47) KMT2APTGS2KDM1AMAPT
SCHEMBL2911623 0.79 MGLL (0.56) KDM4EHPGDKMT2APTGS2KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
EP-1591443-B1 PYRAZOLE DERIVATIVE DAIICHI SANKYO CO LTD (JP) 2010-08-25 EP disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-7622471-B2 Pyrazole derivatives having a pyridazine and pyridine functionality DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2009-11-24 US disclosed
US-20060128685-A1 Pyrazole derivative DAIICHI PHARMACEUTICAL CO., LTD., (JP) 2006-06-15 US disclosed
EP-1591443-A1 PYRAZOLE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2005-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060128685-A1 Pyrazole derivative PTGS1, PTGS2, PTGER1 KDM4E 4322/4885HPGD 18/4885NPC1 2175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.